Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
Henry
S P
SP
Isis Pharmaceuticals, Inc., Carlsbad, CA 92008, USA. shenry@isisph.com
Monteith
D
D
Bennett
F
F
Levin
A A
AA
D000818:Animals; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000633:toxicity*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics* / Q000633:toxicity*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D051571:Protein Kinase C-alpha; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors*; D019908:Proto-Oncogene Proteins c-raf; D013873:Thionucleotides / Q000493:pharmacokinetics* / Q000633:toxicity*
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D016376:Oligonucleotides, Antisense; D011518:Proto-Oncogene Proteins; D013873:Thionucleotides; D017346:Protein Serine-Threonine Kinases; D019908:Proto-Oncogene Proteins c-raf; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha